Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2026-02-01 @ 10:00 PM
Study NCT ID:
NCT01688960
Status:
COMPLETED
Last Update Posted:
2015-03-17
First Post:
2012-09-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
Sponsor:
Regeneron Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
R910-ST-1114
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |